ERIC 2018 | Venetoclax-antibody combinations to come in CLL
Stephan Stilgenbauer
• 25 Oct 2018
The outlook for venetoclax in chronic lymphocytic leukemia (CLL), which is currently approved as a monotherapy in the US and Europe, is extremely promising. Here, Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, discusses the combination of venetoclax and rituximab for relapsed/refractory CLL (MURANO; NCT02005471), and the CLL14 trial of venetoclax and obinutuzumab in the frontline setting (NCT02242942), which will have data as a late breaking abstract at the upcoming American Society of Hematology (ASH) 2018 Annual Meeting and Exposition. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
